Literature DB >> 1601866

Leukocyte chemotactic activity of cyclophilin.

Q Xu1, M C Leiva, S A Fischkoff, R E Handschumacher, C R Lyttle.   

Abstract

During the purification of eosinophil chemotactic factors synthesized by the uterus in response to estrogen we isolated a protein having an N-terminal (15 amino acids) sequence identical to that of rat cyclophilin. Our data demonstrate that cyclophilin, a cytosolic protein isolated from bovine thymocytes, which specifically binds the immunosuppressive drug cyclosporin A, as well as recombinant human cyclophilin, displays eosinophil chemotactic activity. In addition to its chemotactic activity, cyclophilin stimulated the release of peroxidase activity from eosinophils. Maximal chemotactic activity of cyclophilin was achieved at a concentration of approximately 10 nM. At similar concentrations cyclophilin was also able to stimulate the migration of neutrophils. This chemotactic activity could be prevented by the addition of cyclosporin A, but not by a nonimmunosuppressive analog (1-fur-furyl-cyclosporin A) at similar concentrations. This chemotactic activity may represent an additional mechanism by which immunosuppressive drugs function to prevent tissue rejection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601866

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A.

Authors:  T Pushkarsky; G Zybarth; L Dubrovsky; V Yurchenko; H Tang; H Guo; B Toole; B Sherry; M Bukrinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Toxoplasma gondii cyclophilin 18 regulates the proliferation and migration of murine macrophages and spleen cells.

Authors:  Hany M Ibrahim; Xuenan Xuan; Yoshifumi Nishikawa
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

3.  Proteome of Rhipicephalus sanguineus tick saliva induced by the secretagogues pilocarpine and dopamine.

Authors:  C J Oliveira; E Anatriello; I K de Miranda-Santos; I M Francischetti; A Sá-Nunes; B R Ferreira; J M C Ribeiro
Journal:  Ticks Tick Borne Dis       Date:  2013-09-09       Impact factor: 3.744

4.  Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation.

Authors:  Erik J Stemmy; Molly A Balsley; Rosalyn A Jurjus; Jesse M Damsker; Michael I Bukrinsky; Stephanie L Constant
Journal:  Am J Respir Cell Mol Biol       Date:  2011-04-14       Impact factor: 6.914

5.  Evidence for the genetic control of estradiol-regulated responses. Implications for variation in normal and pathological hormone-dependent phenotypes.

Authors:  J S Griffith; S M Jensen; J K Lunceford; M W Kahn; Y Zheng; E A Falase; C R Lyttle; C Teuscher
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

6.  Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes.

Authors:  B Sherry; G Zybarth; M Alfano; L Dubrovsky; R Mitchell; D Rich; P Ulrich; R Bucala; A Cerami; M Bukrinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

7.  Apolipoprotein D Internalization Is a Basigin-dependent Mechanism.

Authors:  Ouafa Najyb; Louise Brissette; Eric Rassart
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

8.  Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection.

Authors:  Xiaochen Tian; Chao Zhao; Hongguang Zhu; Weimin She; Jiming Zhang; Jing Liu; Lanjuan Li; Shusen Zheng; Yu-Mei Wen; Youhua Xie
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

Review 9.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

10.  Interleukin-8 is a cyclosporin A binding protein.

Authors:  H Bang; K Brune; C Nager; U Feige
Journal:  Experientia       Date:  1993-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.